News

The company said that it is working in close alliance with local authorities to secure approval at the quickest time. China Biologic, which had planned to begin preparation

Sanofi Pasteur is expected to leverage Sutro’s cell-free protein synthesis technology in the production of two vaccine candidates. Sutro Biopharma chief executive officer William Newell said the collaboration

Rebif Rebidose was designed as single-use auto-injector for the self-administration of Rebif, a disease-modifying drug. The company anticipates making the product available in a monthly pack in 22

The company obtained market exclusivity for 180 days for Finasteride 1mg tablets in the country. Finasteride tablet is the bioequivalent generic version of Propecia tablets, a prescription medicine

The solution includes new functionality including a rich multi-site architecture which facilitates trial/study set up by therapeutic area, program, partner such as CRO and other configurable attributes. The

Both the companies will work together to evaluate selected protein factors identified by NGM in order to progress the development of potent candidates with glucoregulatory effects of bariatric

AggregateSpend360 is expected to relieve Ranbaxy of resources and time spent to meet the Patient Protection and Affordable Care Act’s (PPACA) state/federal aggregate spend and disclosure reporting requirements.

CAP-T CAP cells, which are immortalized cell lines, produce transient and stable protein. The CAP Technology allows for superior protein yields in a shorter time than traditional methods,

SGI-110 is a DNA-hypomethyating agent that is proven to restore silenced tumour suppressor gene expression in cancer cells by reversal of DNA methylation. Astex chief medical officer Mohammad